Boston Scientific Corporation was founded in 1979 and is headquartered in Marlborough, US

Chairman and Chief Executive Officer

Boston Scientific Corporation has offices in Marlborough, Voisins-le-Bretonneux, Singapore, Arden Hills and in 7 other locations

Marlborough, US (HQ)

100 Boston Scientific Way

Sandton, ZA

Anslow Ln

Üsküdar, TR

45 Ord. Prof. Dr. Fahrettin Kerim Gökay Cd.

Gurugram, IN

48 Sohna Rd

Maple Grove, US

1 Scimed Pl

Huangpu Qu, CN

Meng Zi Lu

Arden Hills, US

4100 Hamline Ave N

Voisins-le-Bretonneux, FR

2 Rue René Caudron

## Revenue (2016) | $8.4 b |

## Revenue growth (2015-16), % | 12% |

## Gross profit | $6 b |

## Gross profit margin (2016), % | 71% |

## Net income (2016) | $347 m |

## Market capitalization (21-Mar-2017) | $33.1 b |

## Closing share price (21-Mar-2017) | $24.4 |

## Cash (31-Dec-2016) | $196 m |

Boston Scientific Corporation's current market capitalization is $33.1 b.

- Source: SEC Filings

Boston Scientific Corporation's revenue was reported to be $8.4 b in FY, 2016 which is a **12.2% increase** from the previous period.

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Revenue | $7.1 b | $7.4 b | $7.5 b | $8.4 b |

## Revenue growth, % | 3% | 1% | 12% | |

## Cost of goods sold | $2.2 b | $2.2 b | $2.2 b | $2.4 b |

## Gross profit | $5 b | $5.2 b | $5.3 b | $6 b |

## Gross profit Margin, % | 70% | 70% | 71% | 71% |

## EBIT | $120 m | ($301 m) | ($327 m) | $447 m |

## EBIT margin, % | 2% | (4%) | (4%) | 5% |

## Pre tax profit | ($223 m) | ($509 m) | ($650 m) | $177 m |

## Net Income | ($121 m) | ($119 m) | ($239 m) | $347 m |

- Source: SEC Filings

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Cash | $217 m | $587 m | $319 m | $196 m |

## Inventories | $897 m | $946 m | $1 b | $955 m |

## Current Assets | $3 b | $3.6 b | $3.5 b | $3.2 b |

## PP&E | $1.5 b | $1.5 b | $1.5 b | $1.6 b |

## Goodwill | $5.7 b | $5.9 b | $6.5 b | $6.7 b |

## Total Assets | $16.6 b | $17 b | $18.1 b | $18.1 b |

## Accounts Payable | $246 m | $262 m | $209 m | $447 m |

## Total Debt | $4.2 b | $3.9 b | $5.7 b | $5.4 b |

## Current Liabilities | $1.8 b | $2.8 b | $2.4 b | $3.6 b |

## Additional Paid-in Capital | $16.6 b | $16.7 b | $16.9 b | $17 b |

## Retained Earnings | ($8.6 b) | ($8.7 b) | ($8.9 b) | ($8.6 b) |

## Total Equity | $6.3 b | $6.7 b | ||

## Debt to Equity Ratio | 0.9 x | 0.8 x | ||

## Debt to Assets Ratio | 0.3 x | 0.2 x | 0.3 x | 0.3 x |

## Financial Leverage | 2.9 x | 2.7 x |

FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} | |
---|---|---|---|---|

## Net Income | ($121 m) | ($119 m) | ($239 m) | $347 m |

## Accounts Receivable | ($101 m) | $53 m | ($17 m) | ($216 m) |

## Inventories | ($7 m) | ($81 m) | $3 m | $40 m |

## Accounts Payable | ($37 m) | $620 m | ($20 m) | $553 m |

## Cash From Operating Activities | $1.1 b | $1.3 b | $600 m | $972 m |

## Purchases of PP&E | ($245 m) | ($259 m) | ($247 m) | ($376 m) |

## Interest Paid | $329 m | $221 m | $283 m | $233 m |

## Income Taxes Paid | $67 m | $74 m | $80 m | $94 m |

FY, 2016 | |
---|---|

## Customers | 35 k^{} |

## Countries | 120^{} |

## Facilities | 13^{} |

- Source: SEC Filings

Acquired Company | Date | Deal Size |
---|---|---|

Symetis | March 30, 2017 | $435 m |

Source: 206 public H-1B filings from Boston Scientific Corporation